Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002375 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
A NA study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00002375: Completed NA study, sponsored by Merck Sharp & Dohme.
NCT00002375 is a NA study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002375, a NA study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications. It is thought that IDV plus NFV will be a safe drug combination for treating HIV.
Interventions
- DRUG Indinavir sulfate
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Phase | NA |
What the finished NCT00002375 record still lists
NCT00002375 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00002375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002375 about?
NCT00002375 is a clinical study titled "Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients". The purpose of this study is to see if it is safe and effective to treat HIV-infected patients with indinavir (IDV) plus nelfinavir (NFV), 2 anti-HIV medications. It is thought that IDV plus NFV will be a safe drug combination for treating HIV.
What is the current status of trial NCT00002375?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants.
What interventions are being tested in trial NCT00002375?
The interventions under investigation include: Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002375?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002375's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant